Objective:To explore efficacy and safety of Aripiprazole adjunctive to antidepressant monotherapy in treatment of incompletely-alleviated depression. Methods:35 patients, diagnosed as depression and partly alleviated by former SSRIs or SNRIs or Mirtazapine treatment, were selected and treated with Aripiprazole additionally. 6 weeks after the treatment, HAMD-17 and TESS were used to evaluate the efficacy. The statistical treatment was performed. Results:A significant reduction in HAMD-17 scores was observed (P<0. 05) and 25% of the patients had been remitted after addition of Aripiprazole. Aripiprazole had a good tolerance and the mean dose was 11. 7mg/d. Conclusions: In the patients who fail to respond to initial antidepressant therapy, adjunctive Aripi﹣prazole is more effective and its mean dose is 11. 7mg/d.%目的：：初步探讨先前药物治疗仅部分有效的抑郁症患者添加阿立哌唑治疗后的有效性及安全性。方法：对35例诊断为抑郁症、先前SSRI或SNRI类或米氮平等药物治疗仅部份有效者添加阿立哌唑治疗，采用HAMD-17及不良反应量表在基线及疗后6周分别进行评定，并进行统计学处理。结果：添加阿立哌唑后HAMD-17量表分显著减少(P<0.05)，并有约25%的患者获临床痊愈，且具有良好的耐受性。阿立哌唑的平均使用剂量为11.7mg/d。结论：添加阿立哌唑可有效治疗先前疗效不佳的抑郁症，阿立哌唑的平均剂量在11.7mg/d。
展开▼
